Errata: Environmental Impact Assessment of Intravenous Versus Subcutaneous Monoclonal Antibodies: A Carbon Footprint Analysis The classification of AML and therapeutic options are now largely driven ...
A breast cancer drug paired with venetoclax significantly enhanced leukemia cell killing and durability in preclinical tests.
Molecular testing is crucial for precision oncology in AML and MDS, but barriers hinder its routine integration. The study analyzed genomic data from 2018 to 2023, focusing on testing rates, types, ...
Preclinical AML studies showed palbociclib plus venetoclax produced stronger, more durable anti‑leukemia activity than venetoclax alone and may overcome resistance.
Academic-community partnerships can reduce patient travel burdens while maintaining high-quality cancer care, as demonstrated by successful high-dose cytarabine consolidation delivery. A flow ...
Examining protein changes in peripheral blood cells just 24 hours after initiating chemotherapy for acute myeloid leukemia (AML) could predict 5-year overall survival, potentially allowing treatment ...
Sanctuary Wealth’s broker/dealer subsidiary will pay $150,000 to settle FINRA allegations that it fell short when developing and testing an anti-money-laundering (AML) program that complied with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback